Dear Editor,

A 46-year-old female presented with a 1-week history of multiple erythema and blisters with pruritus on the extremities. She had received both doses of the SARS-CoV-2 vaccine (Corona Vac developed by Sinovac Life Sciences, Beijing, China), which is an inactivated vaccine. She had no adverse reactions after the first dose. The cutaneous lesions started 4 days after the second dose. She denied systemic diseases, medication history and medicine or food allergic history. Physical examination showed multiple circular erythema and blisters with classic target lesions on the distal extremities (Fig. 1). Multiple erosions involved her lip and oral mucosa (Fig. 2). Laboratory tests including blood routine, hepatic and renal function, T. pallidum particle assay, and HIV antibody serology test were normal or negative. The patient was diagnosed with erythema multiforme (EM) and treated with oral loratadine, rinsing with compound chlorhexidine gargle, and topical corticosteroids. The lesions and symptoms were completely relieved after 2 weeks.

Erythema multiforme is an acute self-limited immune-mediated mucocutaneous disorder, and occasionally occurs with visceral involvement in severe patients. The lesions are distributed preferentially on the distal extremities with classic target lesions and may accompany a mucosal injury. Potential triggering factors of EM include infections (especially herpes simplex virus infections), drugs (containing vaccine), topical agents, and some systemic diseases.

With the worldwide vaccination campaign against the COVID-19 pandemic continuing, increasing cutaneous reactions after the SARS-CoV-2 vaccine have been reported. The most common reported cutaneous reactions included urticaria, local injection-site reaction and morbilliform rash. Other cutaneous reactions included delayed large local reaction, swelling, erythema, painful/itchy sensation, erythromelalgia, a flare of an existing dermatologic condition, vesicular, chilblains, zoster, angioedema, pityriasis rosea, filler reaction, vasculitis, contact dermatitis, rash in a breastfed infant, petechiae, lichen planus and EM. These reported cutaneous reactions were mainly associated with mRNA SARS-CoV-2 vaccine. There are few cutaneous reactions reported about inactivated SARS-CoV-2 vaccine in the literature.

In conclusion, cutaneous adverse reactions from the SARS-CoV-2 vaccine were very rare, mild and generally rapid spontaneous resolution. We should advance notice and reassure the vaccinator. Nevertheless, these adverse events and others should not discourage vaccination against a life-threatening virus.

Acknowledgements

The patients in this manuscript have given written informed consent to the publication of their case details. This content has not been published, nor has it been submitted for publication elsewhere. On behalf of all the contributors, Tao Chen will act as guarantor and will correspond with the journal from this point forward.

Figure 1 Multiple circular erythema and blisters with classic target lesions on the hands.

Figure 2 Erosions on the lip and oral mucosa.
onwards. We hereby transfer, assign, or otherwise convey all copyright ownership, including all rights incidental thereto, exclusively to the journal, if such work is published by the journal.

**Conflict of interest**
The authors have no conflict of interest to declare.

**Funding source**
This article has no funding source.

**Data availability statement**
Data sharing is not applicable to this article, as no new data were created or analysed in this study.

L.-w. Zhang, W.-j. Wang, C.-h. Li, T. Chen*
Department of Dermatovenereology, Chengdu Second People’s Hospital, Chengdu, China
*Correspondence: T. Chen. E-mail: 13980427003@163.com
Li-wen Zhang and Wen-ju Wang contributed equally to this work

**References**
1 Edriss M, Farshchian M, Daveluy S. Localized cutaneous reaction to an mRNA COVID-19 vaccine. J Cosmet Dermatol 2021; 20: 2380–2381.
2 Merhy R, Sarkis AS, Kaikati J, El Khoury L, Ghosn S, Stephan F. New-onset cutaneous lichen planus triggered by COVID-19 vaccination. J Eur Acad Dermatol Venereol 2021; 35: e729–e730. https://doi.org/10.1111/jdv.17504
3 Lopes NT, Pinilla CEO, Gerbase AC. Erythema multiforme after CoronaVac vaccination. J Eur Acad Dermatol Venereol 2021; 35: e717–e719. https://doi.org/10.1111/jdv.17495
4 Corbeddu M, Diociaiuti A, Vinci MR et al. Transient cutaneous manifestations after administration of Pfizer-BioNTech COVID-19 Vaccine; an Italian single-centre case series. J Eur Acad Dermatol Venereol 2021; 35: e483–e485.

DOI: 10.1111/jdv.17689

**Flagellate purpura associated with COVID-19 vaccination**

*Dear Editor,*
Flagellate skin eruptions are characterized by ‘whip-like’ linear or curvilinear streaks, most frequently occurring on the trunk and usually erythematous or pigmented. Common underlying causes include drugs (e.g. bleomycin; peplomycin), diet (e.g. undercooked Shiitake mushrooms) or diseases (e.g. dermatomyositis; adult-onset Still’s disease).1,2 We describe a unique case of flagellate purpura associated with the AstraZeneca (ChAdOx1-S) COVID-19 vaccine.

A systemically well 48-year-old man presented with acute onset of an asymptomatic skin eruption that started to appear 4 h after receiving his first dose of the AstraZeneca COVID-19 vaccine. He denied any recent illness (including no previous SARS-CoV-2 infection and negative COVID-19 test 5 months prior), new medications, ingestion of undercooked Shiitake mushrooms or coining/cupping procedures. Past medical history was significant for immune thrombocytopenia in childhood, which had since resolved. Physical examination revealed linear purpuric patches involving the trunk and bilateral upper extremities; many of these areas had a flagellate appearance (Figures 1 and 2). Laboratory investigations demonstrated neutrophilia and hyperbilirubinemia, but no other abnormalities (including normal platelet count and coagulation profile). Skin biopsies showed perivascular lymphocytic infiltrate with red blood cell extravasation and perifollicular fibrosis, consistent with purpura or a purpuric drug reaction without evidence of vasculitis.

The patient received one dose of a systemic corticosteroid (prednisone 40 mg orally), but no other treatments given the asymptomatic nature. Complete resolution occurred within two weeks without sequelae.

We report a unique case of flagellate purpura following the AstraZeneca COVID-19 vaccine. Given the timeline and absence of other known triggers for this type of presentation, it appears that the COVID-19 vaccine was the underlying cause. The pathogenesis of flagellate skin eruptions is poorly understood. In cases where bleomycin is the cause, it may be secondary to microtrauma (scratching), which results in the drug leaking out.